Evaluating the Risks and Benefits of Phase II and III Clinical Cancer Trials: A Look at Institutional Review Board Members in the Netherlands
van Luijn, H.E.M.
IRB: Ethics and Human Research 2007 January-February; 29(1): 13-17
Showing items related by title, author, creator and subject.
The Evaluation of the Risks and Benefits of Phase II Cancer Clinical Trials by Institutional Review Boards (IRB) Members: A Case Study van Luijn, H.E.M.; Aaronson, N.K.; Keus, R.B.; Musschenga, A.W. (2006-03)There are indications that institutional review board (IRB) members do not find it easy to assess the risks and benefits in medical experiments, although this is their principal duty. This study examined how IRB members ...